Nifty
Sensex
:
:
11419.25
38337.01
-177.65 (-1.53%)
-560.45 (-1.44%)

Pharmaceuticals & Drugs

Rating :
66/99  (View)

BSE: 524804 | NSE: AUROPHARMA

552.40
-17.50 (-3.07%)
19-Jul-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  574.00
  •  575.65
  •  550.00
  •  569.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2521008
  •  13926.05
  •  838.00
  •  550.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 33,394.26
  • 14.12
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 35,868.44
  • 0.45%
  • 2.40

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.87%
  • 3.10%
  • 8.47%
  • FII
  • DII
  • Others
  • 0.06%
  • 13.21%
  • 23.29%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.26
  • 15.24
  • 6.07

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 30.30
  • 12.07
  • 3.42

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 47.02
  • 15.59
  • 6.14

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.09
  • 19.18
  • 17.45

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.05
  • 5.13
  • 3.91

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.09
  • 13.29
  • 12.02

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
5,292.20
4,049.09
30.70%
5,269.67
4,336.11
21.53%
4,751.40
4,435.89
7.11%
4,250.27
3,678.75
15.54%
Expenses
4,234.73
3,260.98
29.86%
4,183.29
3,310.53
26.36%
3,765.13
3,319.01
13.44%
3,539.21
2,844.81
24.41%
EBITDA
1,057.47
788.11
34.18%
1,086.38
1,025.58
5.93%
986.27
1,116.88
-11.69%
711.06
833.94
-14.73%
EBIDTM
19.98%
19.46%
20.62%
23.65%
20.76%
25.18%
16.73%
22.67%
Other Income
32.27
43.83
-26.37%
63.85
33.05
93.19%
26.26
10.27
155.70%
43.73
22.09
97.96%
Interest
50.08
24.72
102.59%
47.65
18.86
152.65%
35.39
17.27
104.92%
29.54
16.87
75.10%
Depreciation
186.62
156.63
19.15%
163.12
138.08
18.13%
163.68
132.08
23.92%
154.53
131.18
17.80%
PBT
816.86
650.59
25.56%
914.42
901.69
1.41%
786.62
977.80
-19.55%
570.72
707.98
-19.39%
Tax
231.12
122.39
88.84%
204.78
306.94
-33.28%
175.42
197.96
-11.39%
115.54
190.99
-39.50%
PAT
585.74
528.20
10.89%
709.64
594.75
19.32%
611.20
779.84
-21.62%
455.18
516.99
-11.96%
PATM
11.07%
13.04%
13.47%
13.72%
12.86%
17.58%
10.71%
14.05%
EPS
9.99
9.02
10.75%
12.16
10.16
19.69%
10.44
13.33
-21.68%
7.78
8.85
-12.09%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
19,563.54
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
4,381.48
3,575.44
3,077.28
Net Sales Growth
18.57%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
5.61%
22.54%
16.19%
 
Cost Of Goods Sold
8,712.65
6,162.23
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
1,963.83
1,574.54
1,533.07
Gross Profit
10,850.89
10,300.80
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
2,417.65
2,000.90
1,544.21
GP Margin
55.46%
62.57%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
55.18%
55.96%
50.18%
Total Expenditure
15,722.36
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
3,418.22
2,752.25
2,809.89
Power & Fuel Cost
-
470.95
437.14
419.26
359.60
349.84
324.72
232.36
208.26
194.91
182.72
% Of Sales
-
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
4.75%
5.45%
5.94%
Employee Cost
-
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
425.07
324.13
240.89
% Of Sales
-
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
9.70%
9.07%
7.83%
Manufacturing Exp.
-
1,534.44
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
511.60
349.01
268.67
% Of Sales
-
9.32%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
11.68%
9.76%
8.73%
General & Admin Exp.
-
1,068.21
997.32
686.38
666.38
283.49
197.83
130.74
120.34
116.94
104.63
% Of Sales
-
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
2.75%
3.27%
3.40%
Selling & Distn. Exp.
-
1,025.85
848.43
901.87
878.98
359.60
305.98
208.20
141.59
143.56
152.87
% Of Sales
-
6.23%
5.69%
6.54%
7.25%
4.44%
5.23%
4.50%
3.23%
4.02%
4.97%
Miscellaneous Exp.
-
298.76
203.97
187.92
227.09
123.20
149.49
111.96
47.53
49.16
152.87
% Of Sales
-
1.81%
1.37%
1.36%
1.87%
1.52%
2.55%
2.42%
1.08%
1.37%
10.63%
EBITDA
3,841.18
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
963.26
823.19
267.39
EBITDA Margin
19.63%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
21.98%
23.02%
8.69%
Other Income
166.11
101.98
115.89
203.80
96.71
21.56
28.54
24.70
71.41
151.49
26.05
Interest
162.66
77.72
66.72
256.70
159.87
310.16
266.64
277.24
64.65
73.09
93.22
Depreciation
667.95
557.97
427.63
392.37
332.61
312.53
248.74
200.53
171.50
149.34
127.60
PBT
3,088.62
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
798.52
752.25
72.62
Tax
726.86
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
225.12
191.36
21.36
Tax Rate
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
28.56%
25.44%
29.41%
PAT
2,361.76
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
563.45
561.21
51.31
PAT before Minority Interest
2,361.99
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
563.06
560.89
51.26
Minority Interest
0.23
0.26
0.47
1.50
4.51
3.78
2.46
0.64
0.39
0.32
0.05
PAT Margin
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
12.86%
15.70%
1.67%
PAT Growth
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
337.94%
-121.92%
0.40%
993.76%
 
Unadjusted EPS
40.37
41.36
39.33
34.67
27.03
40.27
10.09
-4.24
19.57
20.81
18.65

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
2,444.83
1,829.08
1,241.26
Share Capital
58.59
58.59
58.52
29.20
29.15
29.12
29.11
29.11
27.86
26.88
Total Reserves
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
2,415.72
1,801.22
1,214.38
Non-Current Liabilities
583.54
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
645.49
2,245.74
2,409.84
Secured Loans
26.96
177.59
380.10
773.54
1,101.31
1,084.11
862.08
449.74
864.05
987.67
Unsecured Loans
424.24
3.81
362.71
587.93
178.05
64.15
102.55
73.61
1,290.51
1,345.30
Long Term Provisions
55.86
39.13
23.36
24.35
9.18
9.00
4.24
3.09
0.00
0.00
Current Liabilities
8,680.62
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
2,768.49
707.99
570.05
Trade Payables
2,627.44
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
776.35
604.40
514.77
Other Current Liabilities
1,777.80
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
699.09
68.40
28.69
Short Term Borrowings
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
1,234.73
0.00
0.00
Short Term Provisions
244.04
261.36
132.93
218.24
126.60
80.09
66.36
58.32
35.19
26.59
Total Liabilities
20,946.40
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14
4,224.30
Net Block
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
1,738.60
1,710.85
1,398.77
Gross Block
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
2,438.00
2,407.67
1,973.63
Accumulated Depreciation
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
699.40
696.82
574.86
Non Current Assets
8,758.56
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
2,546.75
2,280.47
1,934.61
Capital Work in Progress
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
582.86
570.08
536.30
Non Current Investment
311.52
245.85
122.94
0.14
19.76
22.24
19.86
38.49
-0.46
-0.46
Long Term Loans & Adv.
255.76
256.48
236.56
455.27
789.04
237.82
108.12
110.77
0.00
0.00
Other Non Current Assets
87.56
81.29
32.24
30.25
18.40
18.66
0.12
1.47
0.00
0.00
Current Assets
12,187.84
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
3,321.18
2,506.67
2,289.69
Current Investments
0.02
0.02
0.02
19.65
0.03
0.04
18.68
0.04
0.74
0.72
Inventories
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
1,455.27
1,102.45
877.63
Sundry Debtors
3,084.36
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
1,230.98
956.01
889.76
Cash & Bank
1,261.62
513.48
800.26
469.11
178.58
208.45
70.86
186.72
72.83
127.65
Other Current Assets
1,983.43
1,084.72
464.37
271.67
448.46
407.69
388.98
448.17
374.64
393.93
Short Term Loans & Adv.
760.11
512.09
366.88
387.90
237.22
207.51
216.67
358.87
280.60
333.16
Net Current Assets
3,507.22
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
552.69
1,798.68
1,719.64
Total Assets
20,946.40
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14
4,224.30

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,954.82
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
335.11
425.18
136.03
PBT
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
798.52
752.25
72.62
Adjustment
535.02
408.92
487.50
406.28
515.12
441.54
387.22
197.72
99.77
427.84
Changes in Working Capital
-1,068.98
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
-469.45
-273.72
-334.21
Cash after chg. in Working capital
2,707.22
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
526.79
578.30
166.25
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-752.40
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
-191.68
-153.12
-30.22
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,956.95
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
-599.07
-399.02
-406.28
Net Fixed Assets
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
-396.28
-478.66
-288.52
Net Investments
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
-122.17
-101.50
18.54
Others
-900.40
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
-80.62
181.14
-136.30
Cash from Financing Activity
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
406.98
-84.04
164.99
Net Cash Inflow / Outflow
862.02
-423.72
339.99
-67.95
-54.82
136.62
-118.06
143.02
-57.88
-105.26
Opening Cash & Equivalents
319.63
743.49
403.81
148.02
202.73
65.64
183.71
44.72
102.65
235.68
Closing Cash & Equivalent
1,211.84
319.63
743.50
461.10
148.02
202.73
65.64
183.71
47.19
96.96

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
199.36
159.96
124.50
88.29
64.33
44.74
40.19
41.99
32.83
23.09
ROA
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
10.57%
12.45%
1.30%
ROE
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
26.35%
36.54%
4.33%
ROCE
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
19.29%
21.84%
5.07%
Fixed Asset Turnover
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
1.67
1.72
Receivable days
64.70
89.16
106.53
91.84
93.55
86.28
95.44
89.07
92.25
89.57
Inventory Days
112.70
101.43
100.27
88.91
94.82
105.51
115.91
104.17
98.97
96.37
Payable days
71.58
75.73
81.50
67.49
71.06
57.79
64.70
70.79
72.18
71.28
Cash Conversion Cycle
105.81
114.86
125.30
113.25
117.31
134.00
146.65
122.45
119.04
114.66
Total Debt/Equity
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
1.18
1.88
Interest Cover
42.66
46.80
11.69
14.56
5.94
2.40
0.23
13.19
11.29
1.78

News Update


  • Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets
    11th Jul 2019, 09:01 AM

    Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019

    Read More
  • USFDA pulls up Aurobindo Pharma for 'repeated' failures in CGMP
    4th Jul 2019, 11:47 AM

    The repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs are inadequate

    Read More
  • Aurobindo Pharma receives warning letter from USFDA for API manufacturing facility
    21st Jun 2019, 10:43 AM

    This action follows the earlier inspection of the site by the USFDA in February 2019

    Read More
  • Aurobindo Pharma to invest $200 million on Capex in FY20
    17th Jun 2019, 10:01 AM

    The majority of the CAPEX should be in terms of creating certain both finished dosage and API capacities

    Read More
  • Aurobindo Pharma - Quarterly Results
    28th May 2019, 19:59 PM

    Read More
  • USFDA classifies inspection concluded at Aurobindo Pharma's API facilities
    17th May 2019, 09:18 AM

    The company has already submitted its initial response to USFDA

    Read More
  • Aurobindo Pharma recalls 88,600 vials of Lidocaine injections from US market
    20th Apr 2019, 15:54 PM

    Lidocaine HCI injection is a medication used for local or regional anaesthesia to perform certain surgeries and procedures

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.